

A Nonessential Signal Peptidase II (Lsp) of *Myxococcus xanthus* Might Be Involved in Biosynthesis of the Polyketide Antibiotic TA

YOSSI PAITAN,¹ ELISHA ORR,² ELIORA Z. RON,^{1*} AND EUGENE ROSENBERG¹

Department of Molecular Microbiology and Biotechnology, George S. Wise Faculty of Life Sciences, Tel Aviv University, Ramat Aviv, Israel,¹ and Department of Genetics, University of Leicester, Leicester LE1 7RH, United Kingdom²

Received 7 December 1998/Accepted 14 July 1999

***Myxococcus xanthus* is a gram-negative soil bacterium that produces the polyketide antibiotic TA. In this study, we describe the analysis of an *M. xanthus* gene which encodes a homologue of the prolipoprotein signal peptidase II (SPase II; *lsp*). Overexpression of the *M. xanthus* SPase II in *Escherichia coli* confers high levels of globomycin resistance, confirming its function as an SPase II. The *M. xanthus* gene encoding the *lsp* homologue is nonessential for growth, as determined by specific gene disruption. It has been mapped to the antibiotic TA gene cluster, and the disrupted mutants do not produce the antibiotic, indicating a probable involvement in TA production. These results suggest the existence of more than one SPase II protein in *M. xanthus*, where one is a system-specific SPase II (for TA biosynthesis).**

The secretion of most proteins, in both prokaryotes and eukaryotes, is targeted through amino-terminal signal (or leader) peptides which are specifically cleaved by signal peptidases. Three types of signal peptidases have been described in bacteria: type I, LepB, which is responsible for the majority of exported preproteins; type II, Lsp, which is involved in the processing of lipoproteins; and type III, which is implicated in the processing of pili subunits. Lipoproteins, processed by signal peptidase II (SPase II), are characterized by the modification of a cysteine residue, located within a conserved consensus signal peptide sequence, by glyceryltransferase and *O*-acyltransferase. In all bacteria so far analyzed, SPase II was found to be an essential membrane protein anchored to the cytoplasmic membrane (37). The enzyme recognizes the conserved amino acid motif in the prolipoprotein and cleaves it in front of the cysteine residue. An additional acyl group is then attached to the NH₂-terminal cysteine by *N*-acyltransferase (48).

Several *lsp* genes encoding SPase II have been cloned and sequenced from both gram-positive bacteria (*Staphylococcus aureus* [51], *Staphylococcus carnosus* [47], *Bacillus subtilis* [28], and *Mycoplasma genitalium* [6]) and gram-negative bacteria (*Escherichia coli* [12], *Enterobacter aerogenes* [13], *Pseudomonas fluorescens* [14], and *Haemophilus influenzae* [5]). In all of these gram-negative bacteria, the *lsp* gene is located within the *ilaS-lsp* operon, consisting of *ilaS* and three open reading frames (ORFs), probably with unrelated functions: *orfX*, *orf149*, and *orf316* (20).

Myxococcus xanthus is a gram-negative, gliding, soil bacterium that feeds on proteins and peptides and undergoes a complex life cycle that includes cell-to-cell interactions, signaling, and fruiting body formation (30, 40). In the last process, tens of thousands of cells glide, upon starvation, toward an aggregation center to form a multicellular fruiting body (40), where individual rod-shaped cells differentiate into spherical, dormant, environmentally resistant myxospores. Genetic and biochemical evidence indicates that essential intercellular signaling occurs at multiple stages during the developmental pro-

cess and that cell-to-cell interactions are required for proper transcriptional regulation of developmental genes. *M. xanthus* produces the polyketide antibiotic TA (33, 34), which inhibits cell wall synthesis by interfering with the polymerization of the lipid-disaccharide-pentapeptide (50). The transposon Tn*Slac* (16) was used as a promoter probe to study the expression and transcriptional regulation of genes required for the antibiotic TA biosynthesis (42, 43, 45). A series of transposition mutants blocked in antibiotic production were obtained and assigned the TA operon to a chromosomal segment of at least 36 kb (44). These genes are organized in type I polyketide synthetase modules (25), and the region contains several other genes, all involved in postmodification steps of polyketide biosynthesis (23, 24). Among these genes, we identified a homologue of an SPase II protein.

Information about lipoproteins and their biosynthesis in *M. xanthus* is very scarce. Only a few lipoproteins have been identified; these include MlpA, Tgl, CelA, and two other proteases, PrtA and PrtB. MlpA is a 33-kDa lipoprotein required for normal development of *M. xanthus* and contains the conserved lipo-box sequence at the putative cleavage site of SPase II. When MlpA is expressed in *E. coli* in the presence of globomycin (Glm; a specific inhibitor of SPase II), it behaves as a 35-kDa protein rather than the 33-kDa protein seen with no antibiotic, suggesting that the antibiotic prevents its processing by the *E. coli* SPase II (9). Tgl is a membrane protein required for the production of the type IV pili, which are essential for the social motility involved in the development process of *M. xanthus*. Tgl contains an SPase II recognition sequence at its N terminus, predicting the removal of 19 amino acid residues by SPase II (31, 32). The third lipoprotein, CelA, is an extracellular endoglucanase with an unusual signal peptide which contains three prolines in its N terminus (8a) and is thought to be processed by the type II secretion system. The secretion of extracellular proteases, such as PrtA and PrtB, is required for external protease activities involved in the provision of nutrients to *M. xanthus*. Both proteins contain a lipoprotein signal peptide which is presumably processed by the type II secretion system (29).

In this study, we report the genetic analysis of an SPase II gene encoding a homologue from *M. xanthus*, designated *taG*. We provide evidence for its possible involvement in the bio-

* Corresponding author. Mailing address: Dept. of Molecular Microbiology and Biotechnology, George S. Wise Faculty of Life Sciences, Tel Aviv University, Ramat Aviv, Israel. Phone: 972-3-6409379. Fax: 972-3-6414138. E-mail: eliora@post.tau.ac.il.

synthesis of the antibiotic TA, as well as for the existence of more than one SPase II in this bacterium.

MATERIALS AND METHODS

Bacterial strains and plasmids. The *M. xanthus* strain used in this study was the previously described wild-type strain ER-15 (42). *E. coli* TG1, DH10 β , and XL1-Blue MR were used for cloning and DNA manipulations. *E. coli* Y815 was used for complementation analyses. This strain is temperature sensitive for growth due to a mutation in the SPase II gene. It also carries an IPTG (isopropyl- β -D-thiogalactopyranoside)-inducible *lpp* gene (coding for the major outer membrane lipoprotein, also known as Braun's lipoprotein [4]) on a low-copy-number plasmid pHY001 that encodes for tetracycline resistance (49). The plasmids pKS [negative control, pBluescript KS(+)] and pKSA11 (positive control, contains the complete *ileS-lsp-pyrR* operon from *B. subtilis*) were used in the complementation assays and are described elsewhere (28). A conjugative-tagged Tn1000 transposition system was used for the sequencing, as described elsewhere (26), using *E. coli* MH1578 and MH1599 (39). *E. coli* vectors used for cloning and sequencing were pUC18, pUC19 (22), and SUPERCOS-1 (Stratagene, La Jolla, Calif.). Plasmid pQE9 (Qiagen, Chatsworth, Calif.) was used for the expression of the six-His-SPase II fusion proteins.

Media and growth conditions. *E. coli* was grown at 30, 37, or 42°C, as required, in Luria broth (LB) or on LB agar with the appropriate antibiotics as described previously (35). *M. xanthus* was grown at 32°C on 1 CT-0.5 CTS-CTK medium (44) or CTT medium (10) or on media solidified by 1.5% Bacto agar (Difco) and maintained as described previously (42). LB or AB3 agar medium (Difco) was used for the *lsp* complementation assays as described previously (28).

General DNA procedures. Standard genetic techniques, Southern blot analysis, plasmid preparations, hybridization, and in vitro DNA manipulations were as described earlier (35). Isolation of total DNA from *M. xanthus* was as described elsewhere (3). Cosmid DNA and DNA templates for sequencing reactions and *M. xanthus* electroporation were purified by Qiagen columns. Electroporation of *M. xanthus* was performed as described before (15). Conjugative transposition of Tn1000 for sequencing was done as previously described (26).

DNA sequencing and analysis. Automated DNA sequencing was performed on double-stranded DNA templates by the dideoxynucleotide chain termination method (36), using an Applied Biosystems (Foster City, Calif.) model 373A sequencer. Several cosmids, originating from the chromosomal regions that were found through gene disruption to be essential for TA production, were further analyzed, and the cosmid clone pPYCA111 was subcloned into pUC18 and pUC19 (22) plasmid vectors. A 1.051-kb fragment was sequenced by using the conjugative transposon Tn1000 mutagenesis walking system as described previously (26). Analysis and assembly of the primary DNA sequence data were completed by using the software provided by MacVector[®] 3.5 (International Biotechnologies Inc.) and Sequence Navigator (Applied Biosystems). The searches for DNA and protein sequence homologies in databases were achieved through the use of the BLAST (2) and FASTA (27) programs.

Overexpression of TaG in *E. coli* and complementation tests. In order to construct a recombinant plasmid which would overexpress a six-His-*taG* fusion protein, a 515-bp fragment containing the entire *taG* gene was amplified from the cosmid pPYCA111 by PCR. The forward primer was 5'CCGGATCCATGAACACTCCTTCC3', into which a *Bam*HI site (underlined) was incorporated in order to form an in-frame fusion immediately upstream of the first ATG initiation codon (in bold). The reverse primer, 5'CCCAAGCTTCTATCCGGGACAAC3', incorporated a *Hind*III site (underlined). The same procedure was applied to clone and overexpress an *E. coli* six-His-*lsp* fusion protein. A 521-bp fragment, containing the *E. coli* *lsp* gene, was amplified from *E. coli* chromosomal DNA by PCR. The forward primer was 5'CCGGATCCAGTCAATCGATCTGTCAACAGGG3', into which a *Bam*HI site (underlined) was incorporated immediately upstream of the second codon of the gene (AGT; in bold). A *Hind*III site (underlined) was incorporated into the reverse primer, 5'CCCAA GCTTGCGTCAGCATCGCATCCGGCAGGG3'. The PCR products were digested with *Bam*HI and *Hind*III and cloned into the vector pQE9. In the resulting plasmids, pPYMXSP-II (*M. xanthus taG*) and pPYECSP-II (*E. coli lsp*), the cloned genes were fused in frame to the six-His sequence at their 5' ends and were expressed under the control of a T5 promoter and two *lac* operator sequences. The overexpression of both proteins in *E. coli* was determined by their ability to increase the levels of Gln (a generous gift from M. Inukai, Sankyo Co. Ltd, Tokyo, Japan) resistance in *E. coli* TG1 and Y815, carrying pPYMXSP-II or pPYECSP-II.

The biochemical activity of the *M. xanthus* SPase II in *E. coli* was assayed in vivo by its ability to complement the growth of the temperature-sensitive SPase II mutant *E. coli* Y815, which is sensitive to IPTG at 42°C, due to the accumulation of lipid-modified prolipoprotein (49). Dilutions of *E. coli* Y815 carrying the plasmids pKSA11 and pPYECSP-II (both as positive controls), pQE9 and pKS (both as negative controls), and pPYMXSP-II (*taG*) were plated in two series of LB or AB3 agar medium (Difco) supplemented with 100 μ g of ampicillin ml⁻¹, 15 μ g of tetracycline ml⁻¹, and 0 to 6 mM IPTG. The plates were incubated for 1 day at the permissive temperature (30°C) and then for 7 days at either the permissive (30°C) or the nonpermissive (42°C) temperature. In addition, we monitored the growth of *E. coli* Y815 transformed with plasmids pQE9,

pKSA11, pPYMXSP-II, and pPYECSP-II at 42°C in LB medium supplemented with 100 μ g of ampicillin ml⁻¹, 15 μ g of tetracycline ml⁻¹, and 0 to 6 mM IPTG.

General protein procedures. The procedure for protein extraction from *M. xanthus* strains was similar to that described previously (35). Proteins were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and stained with Coomassie brilliant blue (19). Western blot analysis was performed as described elsewhere (35).

Endoglucanase activity. Extracellular CelA activity was determined by the degradation of carboxymethylcellulose on plates. Twenty colonies from each mutant strain (ER-*taGH* and ER-*taG*) and twenty colonies from the wild-type strain ER-15 were grown on CTT plates containing 1% carboxymethylcellulose (Sigma). After 4 days at 30°C, the utilization of carboxymethylcellulose was determined by the addition of 0.1% Congo red for 10 min, followed by a rinse with 10 ml of 1 M NaCl solution. The colonies that produced active endoglucanase were surrounded by a clear yellow halo on a red background.

General extracellular protease activity. The general extracellular proteolytic activity of *M. xanthus* was examined by proteolysis of skim milk on plates. Twenty colonies from each mutant strain (ER-*taGH* and ER-*taG*) and twenty colonies from the wild-type strain ER-15 were grown on CTT plates containing 2% skim milk. The halo zones surrounding the colonies, as an indication of extracellular proteolytic activity, were measured at different growth times.

Developmental analysis. Fruiting body development was examined on TPM (10 mM Tris-HCl [pH 8.0], 1 mM KH₂PO₄, 8 mM MgSO₄ [final pH 7.6]) agar (1.5%) plates as described previously (17).

Antibiotic TA production assay. The production of the antibiotic TA was determined by the disc assay, as described previously (44).

Nucleotide sequence accession number. The DNA sequence reported here was submitted to the EMBL database and will appear in data libraries under accession no. AJ223309.

RESULTS

Isolation and analysis of the *M. xanthus* SPase II homologue. A cosmid library of *M. xanthus* ER-15 DNA was screened with TA-specific probes (23–25). The recombinant cosmid pPYCA111, which hybridized to these probes, was further characterized through restriction enzyme analysis and subcloned into pUC19. The two contiguous *Sph*I inserts in pPY12 and pPY13, 0.303 and 0.754 kb, respectively, were further analyzed. High-stringency Southern blotting, using the *Sph*I inserts as probes on *Sph*I-restricted *M. xanthus* ER-15 chromosomal DNA, indicated that they are present as single copies in *M. xanthus*. In order to characterize further the cloned region and its deduced function, the nucleotide sequence of the 1.051-kb fragment was determined. A computer homology search of this sequence with available databases revealed significant homology to several SPases II (*Lsp*) and to several cytochrome P450 mono-oxygenases.

The two ORFs within this fragment were identified through the use of the University of Wisconsin Genetic Computer Group (7) and MacVector[®] 3.5 (International Biotechnologies Inc.) programs and were found to be transcribed in the same direction. ORF1, designated *taG*, begins at nucleotide 84 (ATG) and stops at position 596 (TAG), encoding a protein of 171 amino acids ($M_r = 19,489.5$). The frequency of G+C base pairs at the third position of each codon in this frame was found to be 83.2%, a value which is typical of ORFs found in organisms (such as *M. xanthus*) with a high percentage of G+C (total G+C content of this sequence is 63.3%). ORF2, designated *taH*, encodes a cytochrome P450 mono-oxygenase and was found to be involved in TA production. The structure and function of this ORF, which starts at position 648 (ATG) and ends outside the insert of pPY13, is discussed elsewhere (24).

Homology with other lipoprotein SPase II sequences. The deduced amino acid sequence of ORF1 (*taG*) was compared to known SPase II sequences in the EMBL database and was found to display the highest homology to *E. coli* (42% identity and 51.2% similarity) (12) and *P. fluorescens* (31.5% identity and 44.3% similarity) (14) SPase II proteins. These homologies identify ORF1 as an SPase II homologue of *M. xanthus*. The homology between the *M. xanthus* ORF and those of other SPase II proteins, including that of *E. coli*, were analyzed by




FIG. 1. Multiple alignment of the deduced amino acid sequences of SPases II. Shaded boxed letters indicate residues identical in more than four of the six organisms. The predicted membrane-spanning segments of the SPases II (A to D) are indicated by black lines, and the conserved regions (I to III) are indicated by dashed lines.

the program BESTFIT and is displayed in Fig. 1. The sequence alignment reveals several areas of high identity and particularly three generally conserved regions, which are designated I, II, and III (Fig. 1) (28).

Hydrophobicity profile. The hydrophobicity profile (18) of the *M. xanthus* SPase II homologue TaG contains four putative hydrophobic domains (Fig. 1 and 2, segments A to D), which could represent transmembrane domains similar to those proposed for other SPase II proteins (21, 28). Following the proposed positive inside rule (46), a model for the transmembrane structure of TaG is outlined in Fig. 3. In this model, the conserved regions I, II, and III are assigned to specific domains of the proposed structure. Region I is located in the carboxy-terminal part of the first periplasmic loop; region II is located in transmembrane segment C and the amino-terminal part of the second periplasmic loop; and region III is assigned to the

carboxy-terminal moiety of the second periplasmic loop, as well as to transmembrane segment D (Fig. 3).

Specific deletion and disruption of the *taG* gene. The involvement of TaG in TA biosynthesis and its role in cellular growth were assessed in mutant strains with two different types of gene deletion and disruption. First, a kanamycin resistance gene was inserted into pPY06, replacing a 2.33-kb *Bal*I fragment (Fig. 4A), thus deleting the entire *taG* gene and the neighboring gene, *taH*. Second, a *Stu*I restriction site was inserted into pPY06 (using PCR) to replace a 44-bp fragment, starting at position 133 (133 to 177) of pPY12, and a kanamycin resistance gene was inserted into pPY06 at this position, thus disrupting *taG* (Fig. 4B). The resulting plasmids (pPY06B1-Kan and pPY06St-Kan, respectively) (Fig. 4A and B) were linearized and electroporated into *M. xanthus* ER-15. The facts that pUC19 cannot replicate in *M. xanthus* and that the elec-




FIG. 2. Hydrophilicity profile of the *M. xanthus* SPase II protein according to the algorithm developed by Kyte and Doolittle (18). The four major hydrophobic segments are indicated (A to D).

troporated DNA was linear meant that any kanamycin-resistant colony resulted from an integration of the linearized DNA into the chromosome via homologous recombination. Kanamycin-resistant transformants were obtained and shown by Southern blot analysis to have the expected disruptions (see below). This result indicated that this gene encoding the *lsp* homologue is not required for growth and is the first demonstration of a nonessential SPase II protein. The transformants were plated on CTK medium for 5 days, and twenty colonies of each strain were examined for TA production on 0.5 CTS agar. The results clearly indicate that all kanamycin-resistant colonies (20 of 20 colonies) were blocked in TA production, strongly suggesting that *taG* is involved in the production of an active TA molecule but is not essential for normal growth. Two mutants with deletions of *taG* (SPase II), one of each strain, were picked up for further analysis (see below) and were designated ER-taGH (carrying a kanamycin gene replacing all *taG* and *taH* genes) and ER-taG (carrying a kanamycin gene insertion in *taG*).

Southern blot analysis of mutant strains. Chromosomal DNAs from *M. xanthus* ER-15 and ER-taGH were digested with *SalI* and analyzed through Southern hybridization with

three different probes: a kanamycin probe, a specific *taG* probe (the fragment cloned in pPY12), and an insert from the plasmid pPY06 which contains both *taG-taH* and the flanking regions of the deleted 44-bp fragment. The results, presented in Fig. 5, demonstrate that the kanamycin probe hybridized to ER-taGH but not to ER-15, whereas the specific *taG* probe hybridized to ER-15 but not to ER-taGH, indicating that the kanamycin resistance gene indeed replaced the *taG-taH* fragment in ER-15. Similar results, obtained from strain ER-taG, confirmed the insertion of the kanamycin resistance gene into the designated site of the *taG* gene (data not shown).

Overexpression and activity of the *M. xanthus* TaG protein in *E. coli*. The overexpression of *lsp* genes from either gram-negative or gram-positive bacteria was reported to increase the levels of Glm resistance in *E. coli* (28) and was used previously to clone several *lsp* genes (13, 14, 47, 51). We used this finding to determine if *M. xanthus taG* can function as an SPase II in *E. coli*. Since *M. xanthus* genes frequently fail to be expressed in *E. coli* under their own regulatory elements, the *taG* gene was also subcloned into the *E. coli* six-His-tagged expression vector pQE9. The resulting plasmid, pPYMXSP-II, carries the *taG* gene, fused to a 5' six-His sequence, under the control of elements made up of a phage T5 promoter and two *lac* operator sequences. As a control, we cloned the *E. coli lsp* gene in the same way into the same vector (pQE9), forming the plasmid pPYECSP-II.

E. coli TG1 was transformed with various plasmids (pUC19, pQE9, SUPERCOS-1, pPY06, pPYCA111, pPYECSP-II, and pPYMXSP-II; see Materials and Methods), and the resulting strains were grown in LB medium containing Glm (0 to 200 $\mu\text{g ml}^{-1}$) at 30, 37, and 42°C, with the addition of IPTG when required. The results, summarized in Table 1, clearly demonstrate that the *M. xanthus* SPase II homologue (TaG) expressed from the plasmid pPYMXSP-II and the *E. coli* SPase II (Lsp) expressed from the plasmid pPYECSP-II increased the level of Glm resistance from 25 $\mu\text{g ml}^{-1}$ to more than 200 $\mu\text{g ml}^{-1}$ at all temperatures tested. *E. coli* strains carrying any of the other plasmids failed to grow at Glm concentrations higher than 25 $\mu\text{g ml}^{-1}$, the MIC of Glm for *E. coli* TG1. Since two of the plasmids (pPY06 and cosmid pPYCA111) carry the entire native *taG* gene, it can be concluded that this gene fails to be expressed in *E. coli* when controlled by its own regulatory elements. In a similar experiment, the expression of *taG* and the *E. coli lsp* gene in *E. coli* Y815 at 30°C (by plasmids pPYMXSP-II and pPYECSP-II) led to the increase of Glm




FIG. 3. A proposed model for the membrane topology of *M. xanthus* SPase II. The four predicted hydrophobic transmembrane segments (A to D) are indicated. The conserved regions (I to III) are indicated in bold. The numbers represent amino acid residues.




FIG. 4. Specific gene deletion and disruption of *taG* and *taH* by a kanamycin resistance gene insertion into pPY06 replacing a 2.3-kb *Bal*I site, forming the plasmid pPY06B1-Kan (A), and a 44-bp fragment at the beginning of *taG* (at a specific *Stu*I site formed by PCR), forming the plasmid pPY06St-Kan (B). The resulting plasmids were linearized and electroporated into *M. xanthus* ER-15. Restriction enzymes: St, *Stu*I; X, *Xho*I; Bl, *Bal*I; H₂, *Hind*III.

resistance from 25 $\mu\text{g ml}^{-1}$ to more than 200 $\mu\text{g ml}^{-1}$. As with *E. coli* TG1, all other plasmid-containing strains failed to grow at Glm concentrations higher than 25 $\mu\text{g ml}^{-1}$.

The *in vivo* biochemical activity of the *M. xanthus* SPase II in *E. coli* was further examined by determining its ability to complement the growth of *E. coli* Y815, which is temperature sensitive in the presence of IPTG due to the accumulation of lipid-modified prolipoprotein (49). This strain was transformed with plasmids pPYMXSP-II, pPYECSP-II, and pQE9 (negative control), and the resulting transformants were tested for their ability to grow at 42°C (nonpermissive temperature) in

the presence of IPTG (0 to 6 mM). We additionally used, in the same experiment, *E. coli* Y815 transformed with the plasmids pKS (negative control) and pKSA11, which contains the *B. subtilis* *lsp* operon, previously shown to complement this mutation (28). The results are summarized in Table 1 and indicate that the strain transformed with the plasmid pKSA11 (*B. subtilis* *lsp*) formed visible colonies after 4 to 5 days, complementing the temperature-sensitive mutation of *E. coli* Y815 at 42°C in the presence of IPTG. The strain transformed with pPYECSP-II (*E. coli* *lsp*) formed visible colonies after 5 days, the strain transformed with pPYMXSP-II (*M. xanthus* *taG*) formed only a few small visible colonies after 6 to 7 days, and all of the rest of the strains did not form any colonies at all, even after 2 weeks. The results indicate that the *M. xanthus* *taG* gene, expressed from plasmid pPYMXSP-II, confers only limited complementation of the *E. coli* SPase II temperature-sensitive mutation. These results were confirmed by quantitative determination of growth rates in liquid medium of *E. coli* Y815 transformed with plasmids pQE9, pKSA11, pPYMXSP-II, and pPYECSP-II at 42°C in the presence of IPTG (0 to 6 mM). The growth of *E. coli* Y815 transformed with plasmid pQE9 (negative control) was strongly inhibited by the addition of IPTG, while the growth of *E. coli* Y815 transformed with plasmids pPYECSP-II and pKSA11 was IPTG independent, as expected from the complementation of the temperature-sensitive mutation. *E. coli* Y815 transformed with pPYMXSP-II (expressing *taG*) displayed very limited growth in the presence of IPTG, in agreement with the results obtained on solid media, indicating limited or no complementation of the *E. coli* system by TaG. These results imply that TaG is not fully compatible with the *E. coli* lipoprotein processing system, possibly as a result of its more restricted substrate specificity. The findings support the proposal that *M. xanthus* has more than one SPase II protein, one (TaG) of which represents a nonessential, system-specific, prolipoprotein peptidase.

Normal growth and developmental analysis of ER-taGH and ER-taG. The growth rates of ER-taGH and ER-taG were indistinguishable from that of ER-15, indicating that TaG and TaH or any protein processed through their activities is not essential for normal growth. Moreover, all strains (ER-15, ER-taGH, and ER-taG) developed to mature fruiting bodies when examined on TPM agar plates at 30°C, suggesting that the protein encoded by *taG* or any protein processed by this gene




FIG. 5. Southern hybridization analysis of cosmid pPYCA111 DNA (lanes 1) and chromosomal DNA from *M. xanthus* ER-15 (wild type, lanes 2) and ER-taGH (deleted mutant, lanes 3) probed with three different ³²P-labeled probes: a specific *taG* probe (the fragment cloned in pPY12) (A); a kanamycin resistance gene (B); and the insert from the plasmid pPY06, which contains both *taG*-*taH* and their flanking regions (C). The cosmid and chromosomal DNA were digested with *Sal*I and separated on a 1% gel prior to Southern blotting. Hybridization was carried out in 50% formamide at 42°C. Filters were washed in 0.1× SSC (1× SSC is 0.15 M NaCl plus 15 mM sodium citrate)–0.1% sodium dodecyl sulfate at 42 and 50°C (second wash). Marker positions, indicated at the left, are those of *Hind*III-digested λ DNA.

TABLE 1. Biological activity of SPase II genes from various bacteria in *E. coli*^a

Plasmid	Gene	Growth at the following Glm concn ($\mu\text{g ml}^{-1}$)					Complementation growth of <i>E. coli</i> Y815 ^b
		0	10	25	50	200	
None		+	+	+	–	–	–
pUC19		+	+	+	–	–	NT
pQE9		+	+	+	–	–	–
SUPERCOS-1		+	+	+	–	–	NT
pPY06 ^c	<i>taG</i>	+	+	+	–	–	NT
pPYCA111 ^c	<i>taG</i>	+	+	+	–	–	NT
pPYMXSP-II ^d	<i>6 His-taG</i>	+	+	+	+	+	±
pPYECSP-II ^e	<i>6 His-lsp</i>	+	+	+	+	+	+
pKS		NT	NT	NT	NT	NT	–
pKSA11 ^f	<i>B. subtilis lsp</i>	NT	NT	NT	NT	NT	+

^a Bacterial cultures (*E. coli* TG1 and its transformants) were grown in LB containing 0 to 200 $\mu\text{g ml}^{-1}$ and 100 μg of ampicillin ml^{-1} (if required) at 30, 37, and 42°C. The results (+, growth; ±, limited growth; and –, no growth) were the same for all temperatures tested, and therefore, the temperature is not indicated. The same experiment was also performed with *E. coli* Y815 and its transformants, except that Glm resistance was determined only at 30°C. NT, not tested.

^b Complementation growth on LB or AB3 plates.

^c *taG* was cloned with its own regulatory elements.

^d *taG* was cloned under pQE9 regulatory elements.

^e *E. coli lsp* was cloned under pQE9 regulatory elements.

^f *B. subtilis ileS-lsp-pyrR* operon was cloned in pBluescript KS(+) as described elsewhere (28).

product is not essential for the development process of *M. xanthus*. These results suggest that Tgl, which is required for the social motility of *M. xanthus* (31, 32) and consequently for normal development, is not likely to be processed by TaG and hence support the existence of at least two SPase II proteins in *M. xanthus*.

MlpA processing in ER-15, ER-taGH, and ER-taG. The existence of more than one SPase II protein in *M. xanthus* was examined through Southern hybridization analysis, performed on *SalI*-digested chromosomal DNA extracted from the wild-type strain ER-15. For this purpose, we used the *taG* gene as a probe at different hybridization stringencies. At high stringency, only one fragment could be observed, whereas no specific hybridization could be detected at low stringency (data not shown), underlining the need for a different approach to verify the existence of other SPase II proteins in *M. xanthus*. We consequently studied the processing of the lipoprotein MlpA in the mutant strains ER-taGH and ER-taG as well as in the wild-type strain ER-15. The MlpA proteins were purified from cultures grown in 1 CT medium (normal growth) and in 0.5 CTS medium (promoting TA biosynthesis) and analyzed by Western blots, using anti-MlpA polyclonal antibodies (a generous gift from S. Inouye) (9). The data indicate that the size of MlpA is the same in all strains (about 33 kDa), in both 1 CT and 0.5 CTS media. It is therefore likely that MlpA is not processed by TaG, supporting our conclusion that there are at least two SPase II proteins in *M. xanthus*.

Endoglucanase activity (CelA processing). The lipoprotein CelA is an extracellular endoglucanase, containing a type II signal peptide at its N terminus, presumably processed by the type II secretion system. The activity of the extracellular CelA can be determined through the degradation of carboxymethyl cellulose on plates. Twenty colonies from each mutant strain (ER-taGH and ER-taG) and twenty colonies from the wild-type strain ER-15 were grown on CTT agar plates containing 1% carboxymethylcellulose. The degradation of carboxymethylcellulose was determined by the addition of 0.1% Congo red to the plates after 4 days of incubation at 30°C. The formation of similar clear halos around the colonies of all strains clearly demonstrated that both mutant and wild-type strains can degrade carboxymethylcellulose, presumably due to the secretion of an active CelA protein. If the lipoprotein CelA is processed by the type II secretion system, as assumed from its properties

and signal peptide, it has to be processed and secreted by an SPase II protein different from TaG.

General extracellular protease activity. *M. xanthus* feeds on proteins and peptides and secretes many proteolytic enzymes to the medium (8). At least two lipoprotein proteases, PrtA and PrtB (29), which contain a type II signal peptide at their N termini and are thought to be processed by SPase II, were identified and characterized in *M. xanthus*. In an attempt to detect extracellular, proteolytic activity in this bacterium, we determined the proteolysis of skim milk on plates, assuming that the loss of PrtA and PrtB activities (due to the absence of an SPase II activity) would be detected. Twenty colonies from each mutant strain (ER-taGH and ER-taG) and from the wild-type strain ER-15 were grown on CTT plates containing 2% skim milk. No differences in the sizes of halos around the colonies of all strains could be detected, demonstrating that both mutant and wild-type strains possess the same extracellular proteolytic activities. Although the results are indirect, they are compatible with the suggestion that the secreted lipoprotein proteases, including PrtA and PrtB, are likely to be processed by an SPase II protein different from TaG.

DISCUSSION

We determined and analyzed the complete nucleotide sequence of a novel gene (*lsp*) encoding an *M. xanthus* SPase II. The behavior of SPase II mutant strains suggests that the product of the *lsp* gene is required for the production of the antibiotic TA but not for vegetative growth or for the developmental process of the bacterium. As all known SPase II proteins are essential, these results strongly indicate, for the first time, the existence of more than one SPase II protein in a bacterium. One of these proteins has to be a system-specific SPase II, since it is involved in TA production. These conclusions are further reinforced by the observations that the processing of at least three *M. xanthus* lipoproteins (MlpA, CelA, and Tgl), thought to be processed by SPase II, is not impaired in the absence of TaG. The localization of *taG* in the TA gene cluster and its limited complementation of an *E. coli lsp* temperature-sensitive mutant, although confirming Glm resistance, underlines our suggestion for the existence of a system-specific SPase II in *M. xanthus*.

The DNA sequence data of TaG predict a protein of 171

amino acid residues with a calculated molecular mass of 19,489.5 Da, which is consistent with the size of other known SPase II proteins. No ribosomal binding site motif (Shine-Dalgarno) was found 5' to *taG*. In *E. coli*, the SPase II (*lsp*) gene is organized in an operon consisting of *ileS*, *lsp*, and three ORFs: *orfX*, *orf149*, and *orf316* (20). It was therefore suggested that the *lsp* gene in gram-negative bacteria is part of an operon, associated with *ileS*, which encodes the isoleucyl-tRNA synthetase. All gram-negative bacterial *lsp* genes analyzed so far are organized like the *E. coli* cluster. In the gram-positive bacteria, *B. subtilis*, *S. aureus*, *S. carnosus*, and *M. genitalium*, the *lsp* and *ileS* genes are not assigned to one operon, although the *lsp* and *orf4* genes seem to be part of one operon (6, 28, 47, 51). In contrast to other gram-negative bacteria, *M. xanthus* *taG* is not located near *ileS* but rather is part of the antibiotic TA gene cluster and is flanked by genes essential for TA biosynthesis (24). The gene 5' to *taG* is an acyl enzyme which is a homologue of the *B. subtilis* *pksG* gene (1, 38), whereas the gene 3' to *taG* is a cytochrome P450 mono-oxygenase (24). All three genes (acyl enzyme, cytochrome P450, and *taG*) are presumed to be part of one operon involved in TA production, similar to other polyketide synthase systems (11).

The sequence alignment of *taG* with other homologous genes revealed three conserved regions (Fig. 1). The alignment data suggest that regions II and III are more likely to be involved in the catalytic site, which is probably located in the second periplasmic loop. Region I seems to be the least conserved of the three (in *M. xanthus*). This observation is consistent with the suggestion of Sankaran and Wu (37) that SPase II belongs to a novel class of aspartic proteases, as SPase II contains three conserved aspartic acid residues, two of which are located in region II and one that is in region III.

The overexpression of *taG* or the *lsp* gene in *E. coli* confers high Glm resistance, indicating that both proteins are properly synthesized in *E. coli*. Yet, while the *E. coli* *lsp* gene product complements the growth of *E. coli* Y815 at the nonpermissive temperature (42°C), TaG (under the same control elements) conferred a very limited complementation. This result differs from that obtained with the *B. subtilis* SPase II enzyme (28) which complements the same *E. coli* strain (Table 1). The result could mean that the physiological activity of the *M. xanthus* protein is not fully compatible with that of the *E. coli* prolipoprotein processing system. Alternatively, it is possible that although the *M. xanthus* SPase II confers Glm resistance at 42°C, it is not physiologically functional at this temperature, as this organism does not grow at temperatures above 37°C. A more interesting possibility is that *taG* encodes a specific SPase II involved in the biosynthesis of antibiotic TA (as suggested by its gene organization in the TA gene cluster and by the data presented in this study) that has a more restricted substrate specificity and therefore cannot fully complement the *E. coli* SPase II mutation. The observation that the expressed *M. xanthus* protein confers resistance to Glm at 30, 37, and 42°C but confers only limited complementation to the temperature sensitivity of *E. coli* Y815 at 42°C supports the latter possibility, i.e., that *taG* encodes a TA-specific SPase II. Consequently, it is very likely that Glm binding and the processing of lipid-modified prolipoproteins represent two independent activities.

The disruption of *taG* in ER-taG and the deletion of *taG* and *taH* in ER-taGH indicate a possible involvement in TA biosynthesis and suggest that TaG may be required for the production of an active TA molecule. However, it is possible that the block in TA production is the result of a polar effect on *taH* (cytochrome P450) or other genes located 3' to *taG* (in ER-taG). This possibility is difficult to exclude since there are no self-replicating plasmids in *M. xanthus* which could be used

for *trans* complementation of the disrupted and deleted gene(s). A specific nonpolar disruption of *taG* should confirm its involvement in TA biosynthesis. At the moment, the exact function of *taG* in TA biosynthesis and in the processing of lipoproteins is an enigma.

In bacteria, lipoproteins play important roles in nutrient uptake, antibiotic resistance, adhesion mechanisms (targeting bacteria to specific substrates), protein secretion, sporulation, and germination (41). The complete pathway determining the biosynthesis and functions of the *M. xanthus* lipoprotein is as yet unknown, but like gram-positive bacilli and streptomyces, *M. xanthus* undergoes a complex life cycle, including cell-to-cell interactions, signaling, secretion of proteases, and fruiting body formation (40). Lipoproteins may play a part in one or more of these processes.

In summary, this work describes, for the first time, a gram-negative SPase II homologue which is found to be in a gene cluster organized differently from that of other known gram-negative *lsp* genes. In contrast to other bacteria, this gene is not essential for growth, suggesting the existence of more than one SPase II protein in bacteria. The future analysis of all the genes required for TA biosynthesis may provide clues as to the substrate of this SPase II. The observation that TaG appears not to process lipoproteins such as MlpA, CelA, and Tgl and its failure to complement the temperature-sensitive mutation of *E. coli* Y815 strengthen this suggestion. Identification and analysis of other *lsp* genes should clarify the mechanism of type II secretion in *M. xanthus*.

ACKNOWLEDGMENTS

We are very grateful to Sierd Bron and Harold Tjalsma from the University of Groningen, The Netherlands, for generously providing *E. coli* Y815 and plasmids pKS and pKSA11 and for the helpful suggestions in constructing the complementation assay. We are likewise grateful to M. Inukai from Sankyo Co. Ltd., Tokyo, Japan, for his generous gift of globomycin and to S. Inouye for generously providing polyclonal antibodies raised against the MlpA protein.

This work was supported in part by the Pasha Gol Chair for Applied Microbiology (E.R.), the Morris and Manja Leigh Chair for Biophysics and Biotechnology (E.Z.R.), a British Council Clore Foundation Scholarship awarded to Y.P., and grants from the Cancer Research Campaign (no. SP1937/0301) and the Wellcome Trust (no. 038060/Z/93/Z) to E.O.

REFERENCES

- Albertini, A. M., T. Caramori, F. Scoffone, C. Scotti, and A. Galizzi. 1995. Sequence around the 159° region of the *Bacillus subtilis* genome: the *pksX* locus spans 33.6-kb. *Microbiology* **141**:299–309.
- Altschul, S. F., W. Gish, W. Miller, W. Myers, and D. J. Lipman. 1990. Basic local alignment search tool. *J. Mol. Biol.* **251**:403–410.
- Avery, L., and D. Kaiser. 1983. In situ transposon replacement and isolation of spontaneous tandem duplication. *Mol. Gen. Genet.* **191**:99–109.
- Braun, V., and K. Rehn. 1969. Chemical characterization, spatial distribution and function of lipoproteins (murein lipoprotein) of *E. coli* cell wall. The specific effect of trypsin on membrane structure. *Eur. J. Biochem.* **10**:423–438.
- Fleischmann, R. D., M. D. Adams, O. White, et al. 1995. Whole-genome random sequencing and assembly of *Haemophilus influenzae* Rd. *Science* **269**:496–512.
- Fraser, C. M., J. D. Gocayne, O. White, et al. 1995. The minimal gene complement of *Mycoplasma genitalium*. *Science* **270**:397–403.
- Genetics Computer Group. 1991. Sequence analysis software package, version 7. University of Wisconsin Genetics Computer Group, Madison.
- Guespin-Michel, J., B. Letouvet-Pawlak, and F. Petit. 1993. Protein secretion in myxobacteria, p. 235–255. In M. Dworkin and D. Kaiser (ed.), *Myxobacteria II*. American Society for Microbiology, Washington, D.C.
- Guespin-Michel, J. Personal communication.
- Hanlon, W. A., M. Martinez-Canamero, M. Inouye, and S. Inouye. 1995. MlpA, a lipoprotein required for normal development of *Myxococcus xanthus*. *J. Bacteriol.* **177**:7150–7154.
- Hodgkin, J., and D. Kaiser. 1977. Cell-to-cell stimulation of motility in non-motile mutants of *Myxococcus xanthus*. *Proc. Natl. Acad. Sci. USA* **74**:2938–2942.

11. Hopwood, D. A., and D. H. Sherman. 1990. Molecular genetics of polyketides and its comparison to fatty acid biosynthesis. *Annu. Rev. Genet.* **24**:37–66.
12. Innis, M. A., M. Tokunaga, M. E. Williams, J. M. Loranger, S. Y. Chang, S. Chang, and H. C. Wu. 1984. Nucleotide sequence of the *Escherichia coli* prolipoprotein signal peptidase (*lsp*) gene. *Proc. Natl. Acad. Sci. USA* **81**:3708–3712.
13. Isaki, L., M. Kawakami, R. Beers, R. Hom, and H. C. Wu. 1990. Cloning and nucleotide sequence of the *Enterobacter aerogenes* signal peptidase II (*lsp*) and flanking genes. *J. Bacteriol.* **172**:469–472.
14. Isaki, L., R. Beers, and H. C. Wu. 1990. Nucleotide sequence of the *Pseudomonas fluorescens* signal peptidase II (*lsp*) gene. *J. Bacteriol.* **172**:6512–6517.
15. Kashefi, A., and P. L. Hartzell. 1995. Genetic suppression and phenotypic masking of a *Myxococcus xanthus* *frzF*-defect. *Mol. Microbiol.* **15**:483–494.
16. Kroos, L., and D. Kaiser. 1984. Construction of Tn5*lac*, a transposon that fuses *lacZ* expression to exogenous promoters and its introduction into *Myxococcus xanthus*. *Proc. Natl. Acad. Sci. USA* **81**:5816–5820.
17. Kroos, L., A. Kuspa, and D. Kaiser. 1986. A global analysis of developmentally regulated genes in *Myxococcus xanthus*. *Dev. Biol.* **117**:252–266.
18. Kyte, J., and R. F. Doolittle. 1982. A simple method for displaying the hydrophobic character of a protein. *J. Mol. Biol.* **157**:105–132.
19. Laemmli, U. K. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. *Nature (London)* **227**:680–685.
20. Miller, K. W., J. Bouvier, P. Stragier, and H. C. Wu. 1987. Identification of the genes in *Escherichia coli* *iles-lsp* operon. Analysis of multiple polycistronic mRNA made in vivo. *J. Biol. Chem.* **262**:7391–7397.
21. Muñoz, F. J., K. Miller, R. Beers, M. Graham, and H. C. Wu. 1991. Membrane topology of *Escherichia coli* prolipoprotein signal peptidase (signal peptidase II). *J. Biol. Chem.* **266**:17667–17672.
22. Norrander, J., T. Kempe, and J. Messing. 1983. Construction of improved M13 vector. *Gene* **26**:101–106.
23. Paitan, Y., E. Orr, E. Z. Ron, and E. Rosenberg. 1999. A NusG-like transcription anti-terminator is involved in the biosynthesis of the polyketide antibiotic TA of *Myxococcus xanthus*. *FEMS Microbiol. Lett.* **170**:221–227.
24. Paitan, Y., E. Orr, E. Z. Ron, and E. Rosenberg. 1999. Cloning and characterization of a *Myxococcus xanthus* cytochrome P-450 hydroxylase required for biosynthesis of the polyketide antibiotic TA. *Gene* **228**:147–153.
25. Paitan, Y., G. Alon, E. Orr, E. Z. Ron, and E. Rosenberg. 1999. The first gene in the biosynthesis of the polyketide antibiotic TA of *Myxococcus xanthus* codes for a unique PKS module coupled to a peptide synthetase. *J. Mol. Biol.* **286**:465–474.
26. Paitan, Y., N. Boulton, E. Z. Ron, E. Rosenberg, and E. Orr. 1998. Molecular analysis of the DNA *gyrB* gene from *Myxococcus xanthus*. *Microbiology* **144**:1641–1647.
27. Pearson, W. R. 1990. Rapid and sensitive sequence comparison with FASTP and FASTA. *Methods Enzymol.* **183**:63–98.
28. Prágai, Z., H. Tjalsma, A. Bolhuis, J. van Dijk, G. Venema, and S. Bron. 1997. The signal peptidase II (*lsp*) gene of *Bacillus subtilis*. *Microbiology* **143**:1327–1333.
29. Quillet, L., L. Bensmail, S. Barray, and J. Guespin-Michel. 1997. Cloning and sequencing of two genes, *prtA* and *prtB*, from *Myxococcus xanthus*, encoding PrtA and PrtB proteases, both of which are required for the protease activity. *Gene* **198**:135–140.
30. Reichenbach, H. 1993. Biology of the myxobacteria: ecology and taxonomy, p. 13–62. *In* M. Dworkin and D. Kaiser (ed.), *Myxobacteria II*. American Society for Microbiology, Washington, D.C.
31. Rodriguez-Soto, J. P., and D. Kaiser. 1997. The *tgl* gene: social motility and stimulation in *Myxococcus xanthus*. *J. Bacteriol.* **179**:4361–4371.
32. Rodriguez-Soto, J. P., and D. Kaiser. 1997. Identification and localization of Tgl protein, which is required for *Myxococcus xanthus* social motility. *J. Bacteriol.* **179**:4372–4381.
33. Rosenberg, E., B. Vaks, and A. Zuckerberg. 1973. Bactericidal action of an antibiotic produced by *Myxococcus xanthus*. *Antimicrob. Agents Chemother.* **4**:507–513.
34. Rosenberg, E., and M. Varon. 1984. Antibiotics and lytic enzymes, p. 109–125. *In* E. Rosenberg (ed.), *Myxobacteria, development and cell interaction*. Springer-Verlag, New York, N.Y.
35. Sambrook, J., E. F. Fritsch, and T. Maniatis. 1989. *Molecular cloning: a laboratory manual*, 2nd ed. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.
36. Sanger, F., S. Nicklen, and A. R. Coulson. 1977. DNA sequencing with chain-terminating inhibitors. *Proc. Natl. Acad. Sci. USA* **74**:5463–5467.
37. Sankaran, K., and H. C. Wu. 1994. Signal peptidase II—specific signal peptidase for bacterial lipoproteins, p. 17–29. *In* G. von Heijne (ed.), *Signal peptidases*. R. G. Landes Company, Austin, Tex.
38. Scotti, C., M. Piatti, A. Cuzzoni, P. Perani, A. Tognoni, G. Grandi, A. Galizzi, and A. M. Albertini. 1993. A *Bacillus subtilis* large ORF coding for a polypeptide highly similar to polyketide synthases. *Gene* **130**:65–71.
39. Sedgwick, S. G., and B. A. Morgan. 1994. Locating, DNA sequencing and disrupting yeast genes using tagged Tn1000. *Methods Mol. Genet.* **3**:131–140.
40. Shimkets, L. J. 1990. Social and developmental biology of myxobacteria. *Microbiol. Rev.* **54**:473–501.
41. Sutcliffe, I. C., and R. R. B. Russell. 1995. Lipoproteins of gram-positive bacteria. *J. Bacteriol.* **177**:1123–1128.
42. Tolchinsky, S., N. Fuchs, M. Varon, and E. Rosenberg. 1992. Use of Tn5*lac* to study expression of genes required for antibiotic TA production. *Antimicrob. Agents Chemother.* **36**:2322–2327.
43. Varon, M., and E. Rosenberg. 1996. Transcriptional regulation of genes required for antibiotic TA synthesis in *Myxococcus xanthus*. *FEMS Microbiol. Lett.* **136**:203–208.
44. Varon, M., N. Fuchs, M. Monosov, S. Tolchinsky, and E. Rosenberg. 1992. Mutation and mapping of genes involved in antibiotic TA production in *Myxococcus xanthus*. *Antimicrob. Agents Chemother.* **36**:2316–2321.
45. Varon, M., Y. Paitan, and E. Rosenberg. 1997. Trans-acting regulation of antibiotic TA genes in *Myxococcus xanthus*. *FEMS Microbiol. Lett.* **155**:141–146.
46. von Heijne, G. 1994. Membrane protein structure prediction. Hydrophobicity analysis and the positive-inside rule. *J. Mol. Biol.* **225**:487–494.
47. Witke, C., and F. Götz. 1995. Cloning and nucleotide sequence of the signal peptidase II from *Staphylococcus carnosus*. *FEMS Microbiol. Lett.* **126**:233–240.
48. Wu, H. C., and M. Tokunaga. 1986. Biogenesis of lipoproteins in bacteria. *Curr. Top. Microbiol. Immunol.* **125**:127–157.
49. Yamagata, H., C. Ippolito, M. Inukai, and M. Inouye. 1982. Temperature-sensitive processing of outer membrane lipoprotein in an *Escherichia coli* mutant. *J. Bacteriol.* **152**:1163–1168.
50. Zafriri, D., E. Rosenberg, and D. Mirelman. 1981. Mode of action of *Myxococcus xanthus* antibiotic TA. *Antimicrob. Agents Chemother.* **19**:349–351.
51. Zhao, X. J., and H. C. Wu. 1992. Nucleotide sequence of the *Staphylococcus aureus* signal peptidase II (*lsp*) gene. *FEBS Lett.* **299**:80–84.